Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BevG
ChiCTR-OPN-16008570Phase 4Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bevacizumab and gefitinib in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Progression-free survival. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
bevacizumabgefitinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR-OPN-16008570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-16008570.